Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
KPTI Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Karyopharm Therapeutics Inc.NASDAQ: KPTI
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $2.82M, compared with -$4.48M a year earlier. Trailing-twelve-month accounts receivables was $11.89M.
Context
- Accounts receivables amounted to 3.1% of revenue in FY2025, up 0.5 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $2.82M or moves back toward the trailing-twelve-month quarterly average of $2.97M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 4.59M USD
- Year-over-year change
- +220.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.59M | +220.6% |
| FY2024 | 2024-12-31 | (3.8M) | -118.9% |
| FY2023 | 2023-12-31 | 20.12M | +495.8% |
| FY2022 | 2022-12-31 | (5.08M) | +47.1% |
| FY2021 | 2021-12-31 | (9.62M) | — |
Accounts Receivables vs competitors
How KPTI compares with its peers on the latest reported figures
- KPTI's LTM Mar 2026 accounts receivables of $11.89M is the largest of the 4 companies compared; the peer median is $0.
- Its year-over-year change of +385.7% is the highest of 3, against a peer median of -128.6%.
- Accounts receivables amounts to 7.9% of revenue for KPTI, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.89M | +385.7% | — | 7.9% | |
| LTM Mar 2026 | $646K | -49.3% | +1.9% | — | |
| LTM Mar 2026 | $605K | -207.8% | — | 6.7% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding KPTI) | $0 | -128.6% | +1.9% | 6.7% | |
Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (124.09M) | (165.29M) | (143.1M) | (76.42M) | (196.04M) |
| Depreciation & Amortization | 789K | 621K | 530K | 340K | (114K) |
| Deferred Income Tax | 1.45M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 29.78M | 35.4M | 21.71M | 18.43M | 14.05M |
| Change in Working Capital | (23.19M) | (19.99M) | 31.42M | (302K) | 28.27M |
| Accounts Receivables | (9.62M) | (5.08M) | 20.12M | (3.8M) | 4.59M |
| Inventory | (1.46M) | (118K) | 1.18M | (1.7M) | 701K |
| Accounts Payables | (2.85M) | 1.17M | 350K | 1.98M | (1.1M) |
| Other Working Capital | (9.26M) | (15.96M) | 9.76M | 3.21M | 24.09M |
| Other Non-Cash Items | 8.14M | (294K) | (3.28M) | (69.53M) | 78.46M |
| Operating Cash Flow | (107.12M) | (149.55M) | (92.72M) | (127.49M) | (75.37M) |
| Capital Expenditures | (5.71M) | (118K) | 0 | (142K) | 0 |
| Acquisitions (Net) | 5.5M | 104.26M | 0 | 0 | 0 |
| Purchases of Investments | (45.23M) | (226.02M) | (159.15M) | (58.82M) | 0 |
| Sales of Investments | 192.78M | 121.88M | 167.09M | 154.44M | 43.38M |
| Other Investing Activities | (5.5M) | (104.26M) | 0 | 0 | 0 |
| Investing Cash Flow | 141.84M | (104.26M) | 7.94M | 95.47M | 43.38M |
| Debt Repayment | 60M | 0 | 0 | 83.3M | 20.54M |
| Common Stock Issued | 9.9M | 189.76M | 1.12M | 1.45M | 9.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.75M | 3.98M | 0 | (43.11M) | 0 |
| Financing Cash Flow | 73.65M | 193.74M | 1.12M | 41.65M | 30.05M |
| Effect of Forex Changes | (48K) | (488K) | (34K) | (11K) | 20K |
| Net Change in Cash | 108.32M | (60.56M) | (83.69M) | 9.62M | (1.92M) |
| Free Cash Flow | (112.83M) | (149.67M) | (92.72M) | (127.63M) | (75.37M) |
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
Intrinsic Alpha fair value
Locked
Current Price
$7.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.